Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Intravenous TZT-1027, Administered Weekly Times Two, Every Three Weeks, to Patients With Advanced or Metastatic Soft Tissue Sarcomas (STS) With Prior Exposure to Anthracycline-Based Chemotherapy

NCT00064220 is registered in ClinicalTrials.gov with Daiichi Sankyo as lead sponsor.

NCT NCT00064220
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00064220 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Intravenous TZT-1027, Administered Weekly Times Two, Every Three Weeks, to Patients With Advanced or Metastatic Soft Tissue Sarcomas (STS) With Prior Exposure to Anthracycline-Based Chemotherapy
Lead sponsor
Daiichi Sankyo
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2003
Completion date
December 31, 2005
Enrollment
Not reported
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

sarcoma